Everett Cunningham is recorded as Board Member and CEO at Quanterix Corp (QTRX). The newest filing on record that lists Everett Cunningham as Board Member and CEO at Quanterix Corp (QTRX) is dated April 24, 2026. Quanterix Corp reported in an 8-K filed January 8, 2026 that Everett Cunningham was appointed Class II director, effective January 19, 2026. Quanterix Corp reported in an 8-K filed January 8, 2026 that Everett Cunningham was appointed President and Chief Executive Officer, effective January 19, 2026. Illumina, Inc. reported in an 8-K filed January 8, 2026 that Everett Cunningham resigned as Chief Commercial Officer, effective January 16, 2026. Equibles holds 4 filed executive changes naming Everett Cunningham; each is listed under recent activity with its source filing. The proxy statement of Illumina, Inc. reports total compensation of $4,087,101 for Everett Cunningham in fiscal 2025, including a base salary of $650,000. Disclosed compensation is on record for 5 fiscal years. Everett Cunningham has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for Quanterix Corp on August 12, 2026. Quanterix Corp is classified in the Medical Devices industry within the Healthcare sector. Illumina, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Quanterix Corp includes Kevin Hrusovsky (CEO and Chairman), Masoud Toloue (CEO and Chairman), Martin D. Madaus (Chairman) and 7 others.
“Mr. Cunningham was also appointed to serve on the Board as a Class II director, with a term ending at the 2028 annual meeting of stockholders.”
Quanterix Corp Form 8-K, filed January 8, 2026
· Read the filing
“Also on January 8, 2026, the Board appointed Everett Cunningham as President and Chief Executive Officer of the Company, effective January 19, 2026.”
Quanterix Corp Form 8-K, filed January 8, 2026
· Read the filing
Everett Cunningham on recent calls
“And we had our earnings call on Monday morning, so it's kind of fresh. Let me talk about the things that we feel good about at Quanterix. We had our earnings call.”
“And I'm pleased to be with all of you here this morning to bring you up to date on both our second quarter results and our plans for the back half of this year.”
“You know, I'm a lifer when it comes to health care. I've been in health care for 34 years. And my background, you know, in the pharma space, the research tool space, the precision oncology space, lends it really well in terms of the timing and fit with Quanterix.”
“My time at the company has been very exciting and informative, and I'm more confident than ever about the future of Quanterix. Now, in that spirit, I'd like to start off by sharing some of my key observations in my first 100 days with the company.”
“And I'm so excited to be with you this afternoon. I'm looking forward to meeting many of you over the coming weeks and months. Now, for those of you that have not met, I want to share some information about my background and what brought me here to Quanterix.”
